



Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449/PTO</b> <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)			<b>Complete if Known</b>		
			Application Number	10/509,464	
			Filing Date	September 27, 2004	
			First Named Inventor	Christof Niehrs	
			Art Unit	1647	
Examiner Name	Unassigned J. Lockard				
Sheet	1	of	4	Attorney Docket Number	31301-702.831

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/JL/	1	US- 2001/0036643 A1	11-01-2001	James L. Holloway	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
/JL/	2	EP 0 911 399 A2	04-28-1999	Smithkline Beecham Corporation		
	3	WO 00/77239 A2	12-21-2000	Millennium Pharmaceuticals, Inc.		
	4	WO 01/34621 A1	05-17-2001	Human Genome Sciences, Inc.		
	5	WO 02/02603 A2	01-10-2002	Incyte Genomics, Inc.		
	6	WO 02/066509 A2	08-29-2002	Genentech, Inc.		
/JL/	7	WO 02/092015 A2	11-21-2002	Genome Therapeutics Corporation		

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/JL/	8	BOYDEN, LYNN M PH.D. ET AL., High Bone Density Due to a Mutation in LDL-Receptor-related Protein 5, The New England Journal of Medicine, 2002, 346: 1513-1521	
/JL/	9	BROWN SHERYL D ET AL, Isolation and Characterization of LRP6, a Novel Member of the Low Density Lipoprotein Receptor Gene Family, Biochemical and Biophysical Research Communications, 1998, 248: 879-888	

Examiner Signature	/Jon Lockard/	Date Considered	04/11/2008
--------------------	---------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST-3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST-16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	10/509,464	
			Filing Date	September 27, 2004	
			First Named Inventor	Christof Niehrs	
			Art Unit	<del>1645</del> 1647	
Examiner Name	Unassigned J. Lockard				
Sheet	1	of	4	Attorney Docket Number	31301-702.831

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
/JL/	10	DATABASE EMBL [Online] 26 June 2001 (2001-06-26), XP002249432 retrieved from EBI Database accession no. AAB95341		
	11	DATABASE EMBL [Online] 6 November 2001 (2001-11-06), XP002249370 retrieved from EBI Database accession no. AAM93480		
	12	FISCHER LESLIE ET AL, Wnt-3A Enhances Bone Morphogenetic Protein-2-mediated Chondrogenesis of Murine C3H10T1/2 Mesenchymal Cells, Journal of Biological Chemistry, 2002, 277: 30870-30878		
	13	FUJINO TAKAHIRO ET AL, Low-density Lipoprotein Receptor-related Protein 5 (LRP5) is Essential for Normal Cholesterol Metabolism and Glucose-Induced Insulin Secretion, Proc. Natl. Acad. Sci. U S A, 2003, 100: 229-234		
	14	GONG YAOQIN ET AL, LDL Receptor-Related Protein 5 (LRP5) Affects Bone Accrual and Eye Development, Cell, 2001, 107: 513-523		
	15	KATO MASAKI ET AL, Cbfa1-Independent Decrease in Osteoblast Proliferation, Osteopenia, and Persistent Embryonic Eye Vascularization in Mice Deficient in Lrp5, a Wnt coreceptor, The Journal of Cell Biology, 2002, 157: 303-314		
V /JL/	16	LITTLE RANDALL D. ET AL, A Mutation in the LDL Receptor-related Protein 5 Gene Results in the Autosomal Dominant High-Bone-Mass Trait, Am. J. Hum. Genet, 2002, 70: 11-19		

Examiner signature	/Jon Lockard/	Date Considered	04/11/2008
--------------------	---------------	-----------------	------------

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>			<b>Complete if Known</b>		
			Application Number	10/509,464	
			Filing Date	September 27, 2004	
			First Named Inventor	Christof Niehrs	
			Art Unit	4645 1 647	
Examiner Name	Unassigned J. Lockard				
Sheet	1	of	4	Attorney Docket Number	31301-702.831

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
/JL/	17	MAO BINGYU ET AL, LDL-receptor-related protein 6 is a receptor for Dickkopf Proteins, Nature, 2001, 411: 321-325		
	18	MILLER JEFFREY R. ET AL, Signal Transduction Through $\beta$ -catenin and Specification of Cell Fate During Embryogenesis, Genes & Development, 1996, 10: 2527-2539		
	19	NAKAMURA TAKAHIRO ET AL, Molecular Cloning and Characterization of Kremen, a Novel Kringle-containing Transmembrane Protein, Biochimica et Biophysica Acta, 2001, 1518: 63-72		
	20	NUSSE ROEL ET AL, Wnt Genes, Cell, 1992, 69: 1073-1087		
	21	PEIFER MARK, $\beta$ -Catenin as Oncogene: The Smoking Gun, Science, 1997, 275: 1752-1753		
	22	POLAKIS PAUL, Wnt Signaling and Cancer, Genes & Development, 2000, 14: 1837-1851		
/JL/	23	SAADI-KHEDDOUCI SIHEM ET AL, Early Development of Polycystic Kidney Disease in Transgenic Mice Expressing an Activated Mutant of the $\beta$ -catenin Gene, Oncogene, 2001, 20: 5972-5981		

Examiner signature	/Jon Lockard/	Date Considered	04/11/2008
--------------------	---------------	-----------------	------------


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/509,464
				Filing Date	September 27, 2004
				First Named Inventor	Christof Niehrs
				Art Unit	<del>4645</del> 1647
				Examiner Name	Unassigned J. Lockard
Sheet	1	of	4	Attorney Docket Number	31301-702.831

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/JL/  /JL/	24	SURENDRAN KAMESWARAN ET AL, A Role for Wnt-4 in Renal Fibrosis, Am. J. Physiol. Renal Physiol., 2002, 282: 431-441	
	25	VAN ES JOHAN H ET AL, You Wnt some, you lose some: Oncogenesis in the Wnt signaling pathway, Current Opinion in Genetics & Development, 2003, 13: 28-33	
	26	YANG YINGZI ET AL, Wnt5a and Wnt5b Exhibit Distinct Activities in Coordinating Chondrocyte Proliferation and Differentiation, Development, 2003, 130: 1003-1015	
	27	AARON M. ZORN, Wnt Signaling: Antagonistic Dickkops, Current Biology, 2001, 11: R592-595	

Examiner signature	/Jon Lockard/	Date Considered	04/11/2008
--------------------	---------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*